Auxly Cannabis Group Valuation
Is XLY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Sales vs. similares
Price-To-Sales vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of XLY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: XLY (CA$0.02) cotiza por debajo de nuestra estimación de valor razonable (CA$0.09)
Muy por debajo del valor justo: XLY cotiza por debajo de su valor razonable en más de un 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XLY?
Other financial metrics that can be useful for relative valuation.
What is XLY's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CA$62.47m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2x |
Enterprise Value/EBITDA | -12.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does XLY's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 4.4x | ||
MDP Medexus Pharmaceuticals | 0.3x | 5.5% | CA$39.9m |
PCLO PharmaCielo | 16x | n/a | CA$45.8m |
GDNS Goodness Growth Holdings | 0.7x | n/a | CA$74.4m |
TIUM.U Cansortium | 0.7x | 19.8% | US$68.9m |
XLY Auxly Cannabis Group | 0.6x | n/a | CA$62.5m |
Price-To-Sales vs. similares: XLY es un buen valor basado en su Ratio Price-To-Sales (0.2x) comparado con la media de sus homólogos (0.6x).
Price to Earnings Ratio vs Industry
How does XLY's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?
Price-To-Sales vs. Industria: XLY es un buen valor basado en su Ratio Price-To-Sales (0.2x) comparado con la media del sector Canadian Pharmaceuticals (0.9x).
Price to Sales Ratio vs Fair Ratio
What is XLY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.6x |
Fair PS Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular XLY's Price-To-Sales Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Datos insuficientes para mostrar el pronóstico de precios.